In an article published in The Biologist, researcher Dr. David Potter of GW Pharmaceuticals explains: “Metabolic syndrome is a disruption of the way the body metabolises food to produce energy or to store as fat. It is most common in obese people and can lead to major health problems such as Type II diabetes.”
Dr. Potter and his team bred cannabis plants which produce high levels of the compound THCV, which is normally present only in small quantities. THCV is similar to THC (the psychoactive component of the plant) but has a different pharmacology. TGCV is a promising treatment for Type 2 because it helps modulate lipid deposition, cellular energy expenditure, and insulin resistance — the key factors in metabolic syndrome.
To read more about this important study, jump here.Whizzco